Enfusion, Inc. (NYSE:ENFN) Receives Average Recommendation of “Reduce” from Analysts

Shares of Enfusion, Inc. (NYSE:ENFN) have been given a consensus rating of “Reduce” by the five brokerages that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation and two have given a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $10.00.

Separately, Stifel Nicolaus lifted their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th.

Insider Activity

In related news, COO Neal Pawar sold 21,801 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.03. Following the sale, the chief operating officer now owns 1,143,544 shares of the company’s stock, valued at approximately $11,469,746.32. This trade represents a 1.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 36.44% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enfusion

Large investors have recently modified their holdings of the business. Bank of New York Mellon Corp lifted its holdings in shares of Enfusion by 29.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 159,555 shares of the company’s stock valued at $1,359,000 after purchasing an additional 36,257 shares in the last quarter. RiverPark Advisors LLC acquired a new stake in Enfusion during the 2nd quarter worth approximately $68,000. Principal Financial Group Inc. lifted its stake in Enfusion by 15.6% in the second quarter. Principal Financial Group Inc. now owns 56,524 shares of the company’s stock valued at $482,000 after buying an additional 7,611 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Enfusion by 30.3% in the second quarter. Rhumbline Advisers now owns 59,435 shares of the company’s stock valued at $506,000 after buying an additional 13,832 shares during the period. Finally, Victory Capital Management Inc. acquired a new position in shares of Enfusion in the second quarter valued at approximately $183,000. 81.05% of the stock is currently owned by institutional investors.

Enfusion Price Performance

Shares of NYSE:ENFN opened at $10.63 on Wednesday. The company has a 50 day moving average of $9.70 and a 200-day moving average of $9.00. Enfusion has a one year low of $7.52 and a one year high of $11.38. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of 265.82, a P/E/G ratio of 3.98 and a beta of 0.97.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.